

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1.	of	8.
-------	----	----	----

Complete if Known

Application Number	
Filing Date	
First Named Inventor	Michal EISENBACH-SCHWARTZ
Group Art Unit	1647
Examiner Name	Bunner
Attorney Docket Number	EIS-SCHWARTZ-2B

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS


		Foreign Patent Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
Examiner Initials*	Cite No. ¹	Country Code*	Number* Kind Code ⁵ (if known)				
/BEB/	AG	WO 01/36831 A1		05-25-2001	Smithkline Beecham Plc		
	AH	WO 00/60083 A1		10-12-2000	Chiron Corporation		
	AJ	WO 00/31235 A1/3		08-02-2000	Schwab et al		
	AJ	WO 99/53945		10-28-1999	Braun et al		
	AK	WO 99/12966		03-18-1999	Linington et al		
	AL	WO 97/35879		10-02-1997	Immologic Pharma Corp		
	AM	WO 97/14427		04-24-1997	Haglid Kenneth G		
	AN	WO 96/16085 A1		05-30-1996	Neurocrine Biosciences Inc. & Stanford Univ Medical Center		
	AO	WO 96/12737		05-02-1996	Immologic Pharma Corp		
	AP	WO 95/27500		10-19-1995	Brigham & Womens Hospital		
	AQ	WO 95/22344		08-24-1995	Braun et al		
	AR	WO 93/21222		10-28-1993	Ariel et al		
	AS	WO 93/00427 A2		01-07-1993	Erziehungsdirektion Cant. Zurich		
/BEB/	AT	WO 91/01746		02-21-1991	Childrens Medical Center		

**Examiner
Signature**

/Bridget E. Bunner/

Date
Considered

04/01/2007



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet .2

of 8.

Complete If Known

Application Number	
Filing Date	On even date herewith
First Named Inventor	Michal EISENBACH-SCHWARTZ
Group Art Unit	1647
Examiner Name	Brunner
Attorney Docket Number	EIS-SCHWARTZ=2B

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/BEB/	AU	BECKER, et al, "Immunologic Tolerance to Myelin Basic Protein Decreases Stroke Size After Transient Focal Cerebral Ischemia", <u>Proc Natl Acad Sci USA</u> 94(20):10873-10878 (1997)	
	AV	BEN-NUN, et al., "The Rapid Isolation of Clonable Antigen-specific T Lymphocyte Lines Capable of Mediating Autoimmune Encephalomyelitis," <u>Eur J Immunol.</u> , 11:195-199, (1981)	
	AW	BERKOW, et al (Eds), <u>The Merck Manual of Diagnosis and Therapy</u> 16 th Ed., Merck Research Laboratories, Rahway, NJ, pp. 110, 111, 412, 413, 1452-1459, 1488-1490, 1510, 1511, and 1518-1523 (1992)	
	AX	BRADBURY, et al, "NT-3, but not BDNF, Prevents Atrophy and Death of Axotomized Spinal Cord Projection Neurons", <u>Eur J Neurosci</u> ;10(10):3058-3068 (1998)	
	AY	BRITTIS, et al., "Nogo Domains and a Nogo Receptor: Implications for Axon Regeneration", <u>Neuron</u> , 30(1):11-14 (2001)	
	AZ	BROD, et al, "Autologous T-T Cell Activation Mediated by Cell Adhesion Molecules", <u>FASEB J</u> 3(3):A514 (1989)	
	BA	BROSAMLE, et al., "Regeneration of Lesioned Corticospinal Tract Fibers in the Adult Rat Induced by a Recombinant, Humanized IN-1 Antibody Fragment", <u>J Neurosci</u> , 20(21):8061-8068, (2000)	
	BB	BURNS, et al., "Isolation of Myelin Basic Protein-Reactive T-Cell Lines from Normal Human Blood", <u>Cellular Immunology</u> , 81:435-440 (1983)	
	BC	CHEN, et al., "Regulatory T Cell Clones Induced by Oral Tolerance: Suppression of Autoimmune Encephalomyelitis", <u>SCIENCE</u> , 265: 1237-1240 (1994)	
	BD	CHEN, et al, "Nogo-A is a Myelin-Associated Neurite Outgrowth Inhibitor and an Antigen for Monoclonal Antibody IN-1", <u>Nature</u> 403(6768):434-439 (2000)	
	BE	COHEN, "The Cognitive Principle Challenges Clonal Selection", <u>Immunology Today</u> , 13(11):441-444, (1992)	
/BEB/	BF	COHEN, et al, "Autoimmune Maintenance and Neuroprotection of the Central Nervous System", <u>J Neuroimmunol</u> ; 100(1-2):111-114 (1999)	

Examiner
Signature


/Bridget E. Brunner/

Date
Considered

04/01/2007

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08b (08-03)
Approved for use through 07/31/2008. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3

of 8

Complete If Known

Application Number	
Filing Date	On even date herewith
First Named Inventor	Michal EISENBACH-SCHWARTZ
Group Art Unit	1647
Examiner Name	Bunner
Attorney Docket Number	EIS-SCHWARTZ=2B

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/BEB/	BG	ENOCH, et al, "Different Functional Changes Recorded In Open Angle Glaucoma and Anterior Ischemic Optic Neuropathy", <u>Doc Ophthalmol</u> 50(1):169-184 (1980)	
	BH	FADEN, "Experimental Neurobiology of Central Nervous System Trauma" <u>Critical Reviews in Neurobiology</u> 7(3/4):175-186 (1993)	
	BI	FEIGIN, et al, "Recent advances In Huntington's disease: Implication for experimental therapeutics", <u>Curr Opin Neurol</u> 15:483-48 (2002)	
	BJ	FOURNIER, et al, "Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration", <u>Nature</u> 409(6818):341-346 (2001)	
	BK	GEORGE, et al, "Axotomy-Induced Axonal Degeneration Is Mediated by Calcium Influx through Ion-Specific Channels", <u>J Neurosci</u> 15(10):6445-6452 (1995)	
	BL	GRANDPRE, et al., "Identification of the Nogo Inhibitor of Axon Regeneration as a Reticulon Protein", <u>Nature</u> 403(6768):439-444 (2000)	
	BM	GRANDPRE, et al., "Nogo-66 Receptor Antagonist Peptide Promotes Axonal Regeneration." <u>Nature</u> 417(6888):547-551 (2002)	
	BN	HALLIDAY, et al, "Alzheimer's Disease and Inflammation: A Review of Cellular and Therapeutic Mechanisms", <u>Clin Exp Pharmacol Physiol</u> 27:1-8, 2000.	
	BO	HAUBEN, et al, "Autoimmune T Cells As Potential Neuroprotective Therapy For Spinal Cord Injury", <u>Lancet</u> 355(9200):286-287 (2000)	
	BP	HAUBEN, et al, "Passive or active Immunization with myelin basic protein promotes recovery from spinal cord contusion", <u>J Neurosci</u> , 20(17):6421-6430 (2000)	
	BQ	HAUBEN, et al, "Vaccination with a Nogo-A-Derived Peptide after Incomplete Spinal-cord Injury Promotes Recovery Via a T-Cell-Mediated Neuroprotective Response: Comparison with other Myelin Antigens", <u>Proc Natl Acad Sci USA</u> 98(26): 15173-15178 (2001)	
/BEB/	BR	HAY RJ, "Human Cells and Cell Cultures: Availability, Authentication and Future Prospects", <u>Hum Cell</u> 9(3):143-152 (1996)	

Examiner
Signature

/Bridget E. Bunner/

Date
Considered

04/01/2007

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08b (08-03)

Approved for use through 07/31/2008. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 8.

Complete if Known

Application Number	
Filing Date	On even date herewith
First Named Inventor	Michal EISENBACH-SCHWARTZ
Group Art Unit	1647
Examiner Name	Bunner
Attorney Docket Number	EIS-SCHWARTZ=2B

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/BEB/	BS	HICKEY, et al., "T-Lymphocyte Entry into the Central Nervous System", <u>Journal of Neuroscience Research</u> 28:254-260 (1991)	
	BT	HIRSCHBERG, et al., "Accumulation of Passively Transferred Primed T cells Independently of their Antigen Specificity Following Central Nervous System Trauma", <u>Journal of Neuroimmunology</u> 89:88-96 (1998)	
	BU	HOVDA, et al., "Diffuse Prolonged Depression of Cerebral Oxidative Metabolism following Concussive Brain Injury in the Rat: A Cytochrome Oxidase Histochemistry Study", <u>Brain Research</u> 567:1-10 (1991)	
	BV	HUBER, et al, "Nogo-A, a potent inhibitor of neurite outgrowth and regeneration", <u>Biol Chem</u> 381(5-6):407-419 (2000)	
	BW	HUBER, et al, "Patterns of Nogo Mma and Protein Expression in the Developing And Adult Rat and after CNS Lesions", <u>J Neurosci</u> 22(9):3553-3567 (2002)	
	BX	JACKOWSKI A, "Neural Injury Repair: Hope for the Future as Barriers to Effective CNS Regeneration Become Clearer", <u>Br J Neurosurg</u> 9(3):303-317 (1995)	
	BY	JANEWAY, Jr., "The Immune System Evolved to Discriminate Infectious Nonself from Noninfectious Self", <u>Immunology Today</u> 13(1):11-16, (1992)	
	BZ	KANDEL et al (Eds.), <u>Principles of Neural Science</u> Elsevier Science Publishing Co., Inc. (New York, NY), pp. 977-982	
	CA	KERSCHENSTEINER et al., "Activated Human T Cells, B Cells, and Monocytes Produce Brain-derived Neurotropic Factor In Vitro and in Inflammatory Brain Lesions: A Neuroprotective Role of Inflammation", <u>J. Exp. Med.</u> 189(5):865-870, (1999)	
	CB	KRAMER et al., "Gene transfer through the blood-nerve barrier: NGF-engineered neuritogenic T Lymphocytes attenuate experimental autoimmune neuritis", <u>Nature Medicine</u> , 1(11):1162-1166 (1995)	
	CC	LAZAROV et al., "Transplantation of activated macrophages results in partial recovery of paraplegic rats", <u>Nature Medicine</u> , 4(7):814-821 (1998)	
/BEB/	CD	LI et al, "β-Endorphin omission analogs: dissociation of Immunoreactivity from other biological activities", <u>Proc Natl Acad Sci USA</u> 77(6):3211-3214 (1980)	

Examiner
Signature

/Bridget E. Bunner/

Date
Considered

04/01/2007

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08b (08-03)

Approved for use through 07/31/2008, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 8.

Complete if Known

Application Number	
Filing Date	On even date herewith
First Named Inventor	Michal EISENBACH-SCHWARTZ
Group Art Unit	1647
Examiner Name	Bunner
Attorney Docket Number	EIS-SCHWARTZ=2B


OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/BEB/	CE	LIU et al, "Hydroxyl Radicals Generated In Vivo Kill Neurons in the Rat Spinal Cord: Electrophysiological, Histological, and Neurochemical Results", <u>Journal of Neurochemistry</u> , 62(1):37-44 (1994)	
	CF	LIUZZI, et al, "Peripheral Nerve Regeneration", <u>Neurosurg Clin N Am</u> 2(1):31-42 (1991)	
	CG	LOHSE, et al, "Control of Experimental Autoimmune Encephalomyelitis by T Cells Responding to Activated T Cells", <u>Science</u> 244:820-822 (1989)	
	CH	LOHSE, et al, "Inhibition of the Mixed Lymphocyte Reaction by T Cell Vaccination", <u>Eur J Immunol</u> 20:2521-2524 (1990)	
	CI	LOHSE, et al, "Induction of the Anti-Ergotypic Response", <u>International Immunology</u> 4(5):533-539 (1993)	
	CJ	MARTIN, et al, "Gene Specificity and HLS Restriction of Myelin Basic Protein Specific Cytotoxic T Cell Lines from Multiple Sclerosis Patients and Healthy Individuals" <u>The Journal of Immunology</u> , 145(2):540-548 (1990)	
	CK	MERKLER, et al, "Locomotor Recovery in Spinal Cord-Injured Rats Treated with an Antibody Neutralizing the Myelin-associated Neurite Growth Inhibitor Nogo-A," <u>J. Neurosci.</u> 21(10):3665-3673 (2001)	
	CL	MOAELEM et al, "Autoimmune T Cells Protect Neurons from Secondary Degeneration after Central Nervous System Axotomy", <u>Nature Medicine</u> 5(1):49-55 (1999)	
	CM	MOAELEM et al, "Autoimmune T cells Retard the Loss of Function in Injured Rat Optic Nerves", <u>J Neuroimmunol</u> 106(1-2):189-197 (2000)	
	CN	MOR et al, "Pathogenicity of T Cells Responsive to Diverse Cryptic Epitopes of Myelin Basic Protein in the Lewis Rat," <u>The Journal of Immunology</u> , 155(7):3693-3699 (1995)	
	CO	MORRIS et al, "The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and Neuropsychological Assessment of Alzheimer's Disease", <u>Neurology</u> 39(9):1159-1165 (1989)	
/BEB/	CP	OTA et al, "T-cell Recognition of an Immunodominant Myelin Basic Protein Epitope in Multiple Sclerosis," <u>NATURE</u> , 346:183-187 (1990)	

Examiner Signature	/Bridget E. Bunner/	Date Considered	04/01/2007
-----------------------	---------------------	--------------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08b (08-03)
Approved for use through 07/31/2008. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6

of 8.

Complete if Known

Application Number	
Filing Date	On even date herewith
First Named Inventor	Michal EISENBACH-SCHWARTZ
Group Art Unit	1647
Examiner Name	Bunner
Attorney Docket Number	EIS-SCHWARTZ=2B

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cita No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/BEB/	CQ	PAN, et al, "Tumor Necrosis Factor-alpha: A Neuromodulator in the CNS", <u>Neurosci Biobehav Rev</u> 21(5):603-613 (1997)	
	CR	PETTE, et al., "Myelin in Autoreactivity in Multiple Sclerosis: Recognition of Myelin Basic Protein in the Context of HLA-DR2 Products by T Lymphocytes of Multiple-Sclerosis Patients and Healthy Donors", <u>Proc. Natl. Acad. Sci. USA</u> 87:7968-7972(1990)	
	CS	PETROVICH, et al, "Pentoxifylline Suppression of TNF- α Mediated Axonal Degeneration in the Rabbit Optic Nerve," <u>Neurol Res</u> 19(5):551-554 (1997)	
	CT	PLATA SALAMAN C, "Epidermal Growth Factor and the Nervous System", <u>Peptides</u> 12(3):653-663 (1991)	
	CU	POPOVICH, et al, "Cellular Inflammatory Response After Spinal Cord Injury in Sprague-Dawley and Lewis Rats" <u>The Journal of Comparative Neurology</u> , 377:443-464, (1997)	
	CV	POPOVICH, et al, "Concepts of Autoimmunity Following Spinal Cord Injury: Possible Roles for T Lymphocytes in the Traumatized Central Nervous System", <u>Journal of Neuroscience Research</u> , 45:349-363, (1996)	
	CW	POSER CM, "The Role of Trauma in the Pathogenesis of Multiple Sclerosis: A Review," <u>Clin Neurol Neurosurg</u> 96(2):103-110 (1994)	
	CX	PRINJHA, et al, "Animal Studies Raise Hopes for Spinal Cord Repair," <u>Nature</u> 403(6768):383-384 (2000)	
	CY	RAPALINO, et al, "Implantation of Stimulated Homologous Macrophages Results in Partial Recovery of Paraplegic Rats," <u>Nature Medicine</u> , 4(7):814-821 (1998)	
	CZ	SCHLUESENER, et al, "Autoaggressive T Lymphocyte Line Recognizing the Encephalitogenic Region of Myelin Basic Protein: <i>in Vitro</i> Selection from Unprimed Rat T Lymphocyte Populations," <u>The Journal of Immunology</u> , 135(5):3128-3133 (1985)	
	DA	SCHWAB, et al, "Degeneration and Regeneration of Axons in the Lesioned Spinal Cord," <u>Physiol Rev</u> , 76(2):319-370, (1996)	
/BEB/	DB	SCHWARTZ, J, "Synthesis and Trafficking of Neuronal Proteins," <u>Principles of Neural Science</u> , Connecticut Appleton and Lange, 1991, pages 49-65; pg 264-265	

Examiner
Signature

/Bridget E. Bunner/

Date
Considered

04/01/2007

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08b (08-03)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

7

of

8.

Complete if Known

Application Number	
Filing Date	On even date herewith
First Named Inventor	Michal EISENBACH-SCHWARTZ
Group Art Unit	1647
Examiner Name	Bunner
Attorney Docket Number	EIS-SCHWARTZ=2B

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/BEB/	DC	SKOLNICK, et al, "From Genes to Protein Structure and Function: Novel Applications of Computational Approaches in the Genomic Era", <u>Trends Biotechnol</u> 18(1):34-39 (2000)	
	DD	STEECE-COLLIER, et al, "Etiology of Parkinson's Disease: Genetics and Environment Revisited," <u>Proc Natl Acad Sci USA</u> 99(22):13972-13974 (2002)	
	DE	STREILLEN, "Unraveling Immune Privilege", <u>SCIENCE</u> 270:1158-1159 (1995)	
	DF	STREILLEN, "Immune Privilege as the Result of Local Tissue Barrier and Immunosuppressive Microenvironments," <u>Current Opinion in Immunology</u> 5:428-432 (1993)	
	DG	TANABE, et al, "Diversity and pattern in the developing spinal cord", <u>SCIENCE</u> 274(5290):1115-1123 (1996)	
	DH	WANG, et al, "Pathogenesis of axonal degeneration: parallels between Wallerian degeneration and vincristine neuropathy", <u>J Neuropathol Exp Neurol</u> 59(7):599-606 (2000)	
	DI	WEKERLE, "Lymphocyte Traffic to the Brain," <u>The Blood Brain Barrier</u> , Partridge, ed., 1:67-85 Raven Press Ltd. (1993)	
	DJ	WICKELGREN, et al, "Neuroscience. Animal Studies Raise Hope for Spinal Cord Repair," <u>SCIENCE</u> 297(5579):178-181 (2002)	
	DK	WOOLF, et al, "Neuroscience. It Takes More than Two to Nogo," <u>SCIENCE</u> 297(5584):1132-1134, 2002.	
	DL	YOLE, et al, "GM1 Reduces Injury-Induced Metabolic Deficits and Degeneration in the Rat Optic Nerve," <u>Investigation Ophthalmology & Visual Science</u> 33(13):3586-3591 (1992)	
	DM	YOSHINO, et al, "Dynamic Changes in Local Cerebral Glucose Utilization Following Cerebral Concussion in Rats: Evidence of a Hyper- and Subsequent Hypometabolic State," <u>Brain Research</u> 561:1-10 (1991)	
/BEE/	DN	YÜCEL, et al, "Histomorphometric Analysis of Optic Nerve Changes in Experimental Glaucoma", <u>J Glaucoma</u> 8(1):38-45 (1999)	

Examiner
Signature

/Bridget E. Bunner/


Date

Considered

04/01/2007

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.



Application Number	
Filing Date	On even date herewith
First Named Inventor	Michal EISENBACH-SCHWARTZ
Group Art Unit	1647
Examiner Name	Bunner
Attorney Docket Number	EIS-SCHWARTZ=2B

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10810653	
	Filing Date		2006-10-25	
	First Named Inventor	Michal EISENBACH-SCHWARTZ		
	Art Unit	1647		
	Examiner Name	B. E. Bunner		
	Attorney Docket Number	EIS-SCHWARTZ=2B		

U.S.PATENTS							Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Patent citation information please click the Add button.							Add	
U.S.PATENT APPLICATION PUBLICATIONS							Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		
/BEB/	1	20030108528	A1	2003-06-12	M. Eisenbach-Schwartz	Throughout		
If you wish to add additional U.S. Published Application citation information please click the Add button.							Add	
FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
/BEB/	1	WO99/34827	WO	A1	1999-07-15	Yeda Research and Development Co. Ltd.	Throughout	<input type="checkbox"/>
If you wish to add additional Foreign Patent Document citation information please click the Add button.							Add	
NON-PATENT LITERATURE DOCUMENTS							Remove	
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10810653
Filing Date	2006-10-25
First Named Inventor	Michal EISENBACH-SCHWARTZ
Art Unit	1647
Examiner Name	B. E. Bunner
Attorney Docket Number	EIS-SCHWARTZ=2B

/BEB/	1	KARIN, N et al., "Reversal of Experimental Autoimmune Encephalomyelitis by a Soluble Peptide Variant of a Myelin Basic Protein Epitope: T Cell Receptor Antagonism and Reduction of Interferon Gamma and Tumor Necrosis Factor Alpha Production", J. Exp. Med. 180:2227-2237 (1994)	<input type="checkbox"/>
/BEB/	2	KARIN, N et al., "Short Peptide-Based Tolerogens without Self-Antigenic or Pathogenic Activity Reverse Autoimmune Disease," J. Immunol. 160:5188-5194 (1998)	<input type="checkbox"/>
/BEB/	3	MONSONEGO, A et al., "Beneficial Effect of Orally Administered Myelin Basic Protein in EAE-Susceptible Lewis Rats in a Model of Acute CNS Degeneration," J. Autoimmunity 21:131-138 (2003)	<input type="checkbox"/>
/BEB/	4	SCHWARTZ, M et al, "Protective Autoimmunity: Regulation and Prospects for Vaccination after Brain and Spinal Cord Injuries," TRENDS in Molecular Medicine 7:252-258 (2001)	<input type="checkbox"/>
/BEB/	5	SMILEK, D et al, "A Single Amino Acid Change in a Myelin Basic Protein Peptide Confers the Capacity to Prevent Rather than Induce Experimental Autoimmune Encephalomyelitis," Proc. Natl. Acad. Sci. USA 88:9633-9637 (1991)	<input type="checkbox"/>
/BEB/	6	VERGELLI, M. et al, "Differential Activation of Human Autoreactive T cell Clones by Altered Peptide Ligands Derived from Myelin Basic Protein Peptide (87-99)," Eur. J. Immunol. 26:2624-2634 (1996)	<input checked="" type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Bridget E. Bunner/	Date Considered	04/01/2007
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.